Table 1 Clinical and demographic characteristics of all patients, and stratified by BM response
Characteristics | All pts, n = 58 | BM-NR, n = 29 | BM-PR, n = 16 | BM-CR, n = 13 |
|---|---|---|---|---|
PV/ET, no. | 27/31 | 15/14 | 5/11 | 7/6 |
Median age, years (range) | 52 (19–75) | 53 (19–72) | 55 (33–70) | 52 (23–75) |
JAK2 V617F-positive patients, no (%) | 42 (72) | 22 (76) | 9 (56) | 11 (84) |
Other driver mutations, no (%) | CALR 6, MPL 2, TN 8 | CALR 1, TN 6 | CALR 5, MPL 2 | TN 2 |
JAK2 V617F allele burden, median (range) | 34 (3–89) | 32.4 (3–82) | 41 (18–89) | 30 (5–76) |
Abnormal karyotype, no | 3 | – | 2 | 1 |
Median white blood cell count, 109/L (range) | 9 (4–19) | 9 (4–19) | 9 (3–19) | 8 (4–12) |
Median hemoglobin, g/dL (range) | 13 (9–19) | 14 (12–17) | 13 (9–18) | 13 (12–19) |
Median platelet count, 109/L (range) | 721 (128–1646) | 629 (185–1646) | 866 (128–1423) | 420 (236–1020)* |
Significant splenomegaly, n (% of known)a | 9/55 (16) | 5/28 (18) | 3/15 (20) | 1/12 (8) |
Disease-related symptoms, n (%) | 30 (52) | 17 (59) | 6 (38) | 7 (54) |
No. of previously treated (%) | 36 (62) | 16 (55) | 11 (69) | 9 (69) |